贝前列素钠与尿毒清在慢性肾功能衰竭维持性血液透析患者中的应用效果研究  

Study on application effect of beraprost sodium and Niaoduqing in patients with chronic renal failure on maintenance hemodialysis

作　　者：潘耀令 PAN Yao-ling(Nephrology Department,Yantai Port Hospital,Yantai 264001,China)

机构地区：[1]烟台海港医院肾内科,264001

出　　处：《中国现代药物应用》2025年第5期22-25,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨贝前列素钠与尿毒清在慢性肾功能衰竭(CRF)维持性血液透析(MHD)患者中的应用效果。方法选取接受MHD治疗的CRF患者110例,按照随机数字表法分为对照组(55例)及研究组(55例)。对照组患者接受贝前列素钠治疗,研究组患者在对照组基础上联用尿毒清颗粒治疗。比较两组患者的临床疗效、肾功能指标[尿素氮(BUN)、血肌酐(Scr)、肾小球滤过率(eGFR)]、炎症因子[白介素-6(IL-6)、C反应蛋白(CRP)]、不良反应发生情况。结果与对照组的72.73%相比,研究组总有效率90.91%更高,差异有统计学意义(P<0.05)。治疗后,两组BUN、Scr与治疗前相比更低,eGFR与治疗前相比更高,且研究组BUN(22.65±3.02)mmol/L、Scr(550.63±22.02)μmol/L较对照组的(28.65±3.45)mmol/L、(590.05±23.02)μmol/L更低,eGFR(45.55±5.02)ml/(min·1.73 m^(2))较对照组的(40.45±4.05)ml/(min·1.73 m^(2))更高,差异有统计学意义(P<0.05)。治疗后,两组IL-6、CRP与治疗前相比更低,且研究组IL-6(54.46±6.85)ng/L、CRP(7.00±0.58)mg/L较对照组的(60.65±5.77)ng/L、(8.12±0.60)mg/L更低,差异有统计学意义(P<0.05)。两组不良反应发生率比较,无差异性(P>0.05)。结论贝前列素钠联合尿毒清在接受MHD治疗的CRF患者中具有较好的应用效果,能够改善其肾功能,抑制炎症反应,安全可靠。Objective To explore the application effect of beraprost sodium and Niaoduqing in patients with chronic renal failure(CRF)on maintenance hemodialysis(MHD).Methods A total of 110 CRF patients receiving MHD were selected and divided into control group(55 cases)and study group(55 cases)according to random numerical table.The control group was treated with beraprost sodium,and the study group was treated with Niaoduqing granule on the basis of the control group.Comparison of the clinical efficacy,renal function indicators[blood urea nitrogen(BUN),serum creatinine(Scr),estimated glomerular filtration rate(eGFR)],inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP)]and the occurrence of adverse reactions between the two groups.Results The total effective rate of the study group was 90.91%,which was higher than 72.73%of the control group,and the difference was statistically significant(P<0.05).After treatment,BUN and Scr in both groups were lower than those before treatment,and eGFR was higher than that before treatment;the study group had BUN of(22.65±3.02)mmol/L and Scr of(550.63±22.02)μmol/L,which were lower than(28.65±3.45)mmol/L and(590.05±23.02)μmol/L in the control group;the study group had a higher eGFR of(45.55±5.02)ml/(min·1.73 m^(2))than(40.45±4.05)ml/(min·1.73 m^(2))in the control group;the difference was statistically significant(P<0.05).After treatment,IL-6 and CRP in both groups were lower than those before treatment;the study group had IL-6 of(54.46±6.85)ng/L and CRP of(7.00±0.58)mg/L,which were lower than(60.65±5.77)ng/L and(8.12±0.60)mg/L in the control group;the difference was statistically significant(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of beraprost sodium and Niaoduqing has a good application effect in CRF patients receiving MHD,and can improve their renal function,inhibit inflammatory factors.It is safe and reliable.

关 键 词：贝前列素钠 尿毒清 维持性血液透析 慢性肾功能衰竭 

分 类 号：R692.5[医药卫生—泌尿科学]